Nasal spray flu vaccine may help prevent influenza in healthy children

An influenza virus vaccine delivered as a nasal spray, appears to be effective in protecting healthy children against certain strains of influenza, according to an article in the January issue of The Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

Each winter, influenza causes significant illness in all age groups, according to the article. The U.S. Food and Drug Administration recently approved an influenza virus vaccine (cold-adapted trivalent influenza virus vaccine, or CAIV-T) administered in the form of a nasal spray for use in healthy children and adults aged 5 through 49 years. Previous studies have shown that the nasal spray was successful in preventing influenza A (H3N2) and B infections in children 15 months old to about 6 years old, and was effective in preventing certain strains of the influenza virus from infecting adults. However, the ability of CAIV-T to prevent natural influenza A (H1N1) infection is unknown.

Manjusha J. Gaglani, M.B.B.S., from the Scott & White Memorial Hospital and Clinic, Temple, Tex., and colleagues assessed the effectiveness of CAIV-T in healthy children during the 2000-2001 influenza A (H1N1) epidemic.

The incidence of respiratory infections that resulted in a medical visit among 3,794 healthy children aged 1.5 to 18 years who received the CAIV-T vaccine at least once in 1998, 1999 and/or 2000 was compared with the incidence among 9,325 healthy non-recipient children and adolescents in the same communities, and 16,264 in two other communities.

The researchers found, “Significant direct effectiveness of CAIV-T for prevention of [acute respiratory illness] in all age groups and in all children vaccinated in 2000 was observed during the entire influenza A and B epidemic. Direct effectiveness in all children and children aged 1.5 to 4 and 5 to 9 years during the six weeks when influenza A (H1N1) viruses predominated documented effectiveness of CAIV-T against natural influenza A (H1N1) infection for the first time,” write the authors.

(Arch Pediatr Adolesc Med. 2004;158:65-73. Available post-embargo at archpediatrics.com)

Editor’s Note: This study was supported by a grant from the National Institutes of Health, Bethesda, Md., and MedImmune, Inc., Mountain View, Calif., which provided the investigational intranasal influenza vaccine.

For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org .

Media Contact

Scott Clark EurekAlert!

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Memory Self-Test via Smartphone

… Can Identify Early Signs of Alzheimer’s disease. Dedicated memory tests on smartphones enable the detection of “mild cognitive impairment”, a condition that may indicate Alzheimer’s disease, with high accuracy….

The Sound of the Perfect Coating

Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…

Partners & Sponsors